1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
GeneReach Biotechnology Corp.

GeneReach Biotechnology Corp.

TTPEX:4171
17.00
TWD
-0.10
(-0.58%)
-0.80EPS
963.73MMarket Cap
GeneReach Biotechnology Corp.
TPEX:4171
(Taipei Exchange)

Recent

price

17.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
3.58
2.33
2.23
2.96
3.07
3.09
3.2
3.86
6.7
14.92
17.61
13.05
3.92
3.59
4.08
4.16
Revenue per Share
0.12
-0.55
-1.35
-0.67
-0.51
-0.8
-0.99
0.59
1.41
4.48
6.55
3.85
-2.89
-2.07
-1.93
-0.75
Basic EPS, GAAP
-2.07
-2.62
-0.86
-0.36
-0.18
0.01
-0.17
0.07
-0.46
1.83
5.8
5.35
-1.05
-0.55
-0.44
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.5
3.64
1.2
0.28
- -
- -
Dividend per Share
11.85
6.57
5.22
7.47
6.97
6.29
5.16
5.89
9.67
14.15
18.27
18.58
14.48
12.48
10.24
10.07
Book Value per Share
10.1
5.65
4.56
7.01
6.61
6.02
4.96
5.72
9.53
14
18.1
18.42
14.27
12.26
9.97
9.82
Tangible Book Value per Share
30
43
43
45
49
49
49
49
55
57
57
57
57
57
57
57
Basic Weighted Avg Shares
106
100
96
134
149
150
155
187
366
857
1,012
750
225
206
233
238
Sales/Revenue/Turnover
3.67
-31.23
-60.33
-31.62
-18.07
-17.75
-13.78
6.81
31.15
41.7
48.16
32.03
-92.19
-65.8
-37.34
-24.93
Operating Margin (%)
8
11
21
21
22
20
16
14
26
52
60
65
69
75
71
61
Depreciation Expense
4
-23
-58
-30
-25
-39
-48
29
77
257
377
221
-166
-119
-110
-43
Net Income, GAAP
8.23
- -
- -
- -
- -
- -
- -
- -
11.23
22.19
21.07
20.15
- -
- -
- -
- -
Effective Tax Rate (%)
3.35
-23.45
-60.52
-22.77
-16.64
-25.73
-30.97
15.24
21.1
30.02
37.21
29.51
-73.75
-57.5
-47.38
-18.1
Profit Margin (%)
99
134
68
179
122
150
-57
60
312
554
902
685
426
355
283
280
Working Capital
102
136
133
115
94
189
- -
- -
72
129
305
124
98
85
72
66
LT Debt
218
282
224
363
339
306
251
311
593
858
1,088
1,103
862
725
597
581
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
14.85
30.37
28.43
12.49
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
9.7
28.93
30.44
15.43
- -
- -
- -
- -
Return on Capital (%)
- -
-9.34
-22.93
-10.36
-7.07
-12
-17.3
10.59
18.28
37.6
40.44
20.91
-17.5
-15.33
-16.92
-7.26
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
154
151
154
LT Borrowings
- -
- -
- -
LT Finance Leases
72
68
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
57
57
Market Capitalization
1,077
1,080
964

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
484
481
479
Cash, Cash Equivalents & STI
405
406
396
Accounts Receivable, Net
39
33
32
Inventories
33
33
42
Total Current Liabilities
201
192
199
Payables & Accruals
- -
- -
- -
ST Debt
154
151
154
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.44%
-5.45%
-17.75%
Free Cash Flow
-359.11%
4.33%
-20.63%
Net Income, GAAP
11.87%
-41.14%
-7.12%
Sales/Revenue/Turnover
18.08%
-14.69%
12.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
46
43
62
55
206
2025
52
54
53
72
233
2026
52
60
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.35
-0.63
-0.47
-0.62
-2.07
2025
-0.18
-1.16
-0.65
0.05
-1.93
2026
-0.09
-0.07
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.28
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
GeneReach Biotechnology Corp. is a biotechnology company primarily engaged in the research, development, manufacture, and sales of molecular diagnostics products. The company's main products include nucleic acid detection reagents, medical DNA/RNA extraction kits, real-time PCR instruments, and automated nucleic acid extraction instruments. It serves markets in clinical diagnostics, animal health, food safety, and agricultural biotechnology. The company operates primarily in Taiwan and China, with its headquarters located in Taichung, Taiwan. Founded in 2002, GeneReach provides comprehensive molecular diagnostic solutions, including testing kits for infectious diseases, genetic mutations, and foodborne pathogens. In the last 1-2 years, GeneReach Biotechnology Corp. has focused on expanding its strategic collaborations and product portfolios, particularly emphasizing the development and launch of advanced automation solutions for nucleic acid extraction to improve efficiency and throughput. The company has also strengthened its presence in the global molecular diagnostics market through new partnerships and enhancements in its real-time PCR product lines, targeting broader applications in human and veterinary diagnostics. These efforts reflect a strategic shift toward integrating automated testing platforms and expanding its footprint in both clinical and agricultural markets to address growing demand for rapid, reliable molecular testing solutions. GeneReach operates in the biotechnology sector with business segments including molecular diagnostics reagents and instrumentation, targeting hospitals, laboratories, research institutions, and agricultural enterprises. It offers a range of branded products designed for PCR-based testing, gene mutation detection, infectious disease identification, and pathogen screening. The company is a key player in the Asia-Pacific region, leveraging its technological expertise and manufacturing capabilities to serve a diverse customer base across healthcare and food safety industries. GeneReach Biotechnology Corp. is publicly traded under the ticker 4171.TWO and continues to invest in innovation to support growth in the molecular diagnostics field.